Natera’s Signatera Test Integrated into Phase III Bladder Cancer Trial
The ARCHER study will evaluate shortened radiation therapy while using ctDNA testing to monitor treatment response and disease recurrence.
Tag: Natera
All
Latest
All
Latest
Natera Named UnitedHealthcare Preferred Lab Network
Natera, a global provider in cfDNA testing, has been selected to participate in UnitedHealthcare's Preferred Laboratory Network.
All
LatestMolDx Issues LCD for Noninvasive Kidney Transplant Rejection Test
The LCD represents a major reimbursement milestone on the company’s path to commercialization in 2019.
